Clinical Trial Update: Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

This clinical trial update notes that a Phase 2 study of Pulmonart (docetaxel) for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pulmonart (Docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Lung Neoplasms | Phase 2 | Status: COMPLETED